Haemonetics Gets FDA Clearance For Enhancements to NexSys PCS System
Provided by
Dow Jones
By Will Feuer
Medical-technology company Haemonetics said it has received clearance from the Food and Drug Administration for enhancements to its NexSys PCS plasma-collection system.
The enhancements include a new plasma collection bowl and technology engineered to reduce procedure time, which the company expects to average between 33 minutes and 38 minutes.
The company said it is planning an initial market release of the system with its enhancements in the coming months.
The plasma business is Haemonetics' largest in terms of revenue, posting $131.2 million in the fourth quarter, up about 30% from a year ago.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
June 22, 2023 06:52 ET (10:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters